Performance of Nomogram Prediction Combining MiRNAs in Cervical Mucus, HPV Genotype and Age for Cervical Cancer and its Precursor Lesions

Cervical cancer is the fourth most common cancer in women worldwide. Although cytology or HPV testing is available for screening, these techniques have their drawbacks and optimal screening methods are still being developed. Here, we sought to determine whether aberrant expression of miRNAs in cervical mucus could be an ancillary test for cervical neoplasms. The presence of miRNAs in 583 and 126 patients (validation and external cohorts) was determined by real-time RT-PCR. Performance of a combination with five miRNAs (miR-126-3p, -451a -144-3p, -20b-5p and -155-5p) was estimated by ROC curve analysis. Predicted probability (PP) was estimated by nomograms comprising -ΔCt values of the miRNAs, HPV genotype and age. A combination of five miRNAs showed a maximum AUC of 0.956 (95%CI: 0.933-0.980) for discriminating cancer. Low PP scores were associated with good prognosis over the 2-year observation period (p<0.05). Accuracy for identifying cancer and cervical intraepithelial neoplasia (CIN)3+ by nomogram was 0.983 and 0.966, respectively. PP was constant with different storage conditions of materials. We conclude that nomograms using miRNAs in mucus, HPV genotype and age could be useful as ancillary screening tests for cervical neoplasia.

[1]  R. Reis,et al.  MicroRNA Biomarkers of High-Grade Cervical Intraepithelial Neoplasia in Liquid Biopsy , 2021, BioMed research international.

[2]  M. Paryan,et al.  Pap Smear miR-92a-5p and miR-155-5p as Potential Diagnostic Biomarkers of Squamous Intraepithelial Cervical Cancer , 2021, Asian Pacific journal of cancer prevention : APJCP.

[3]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[4]  B. Das,et al.  Urine miRNA signature as a potential non-invasive diagnostic and prognostic biomarker in cervical cancer , 2020, Scientific Reports.

[5]  Wei-Chung Cheng,et al.  Identification and validation of a miRNA-based prognostic signature for cervical cancer through an integrated bioinformatics approach , 2020, Scientific Reports.

[6]  Weiying Lu,et al.  Circulating exosomal miR-125a-5p as a novel biomarker for cervical cancer , 2020, Oncology letters.

[7]  K. Baldy-Chudzik,et al.  MicroRNA-Based Fingerprinting of Cervical Lesions and Cancer , 2020, Journal of clinical medicine.

[8]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[9]  Jinhui Liu,et al.  A microRNA-Messenger RNA Regulatory Network and Its Prognostic Value in Cervical Cancer. , 2020, DNA and cell biology.

[10]  R. Crawford,et al.  The early detection of cervical cancer. The current and changing landscape of cervical disease detection , 2020, Cytopathology : official journal of the British Society for Clinical Cytology.

[11]  C. Gieger,et al.  Impact of long-term storage and freeze-thawing on eight circulating microRNAs in plasma samples , 2020, PloS one.

[12]  S. de Sanjosé,et al.  Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): a systematic review and meta-analysis , 2019, British Journal of Cancer.

[13]  J. Fregnani,et al.  Identification and performance evaluation of housekeeping genes for microRNA expression normalization by reverse transcription-quantitative PCR using liquid-based cervical cytology samples , 2019, Oncology letters.

[14]  C. Lombardo,et al.  Nomogram-based prediction of cervical dysplasia persistence/recurrence. , 2019, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[15]  K. B. de Oliveira,et al.  From squamous intraepithelial lesions to cervical cancer: Circulating microRNAs as potential biomarkers in cervical carcinogenesis. , 2019, Biochimica et biophysica acta. Reviews on cancer.

[16]  M. Wood,et al.  Extracellular microRNAs exhibit sequence-dependent stability and cellular release kinetics , 2019, RNA biology.

[17]  P. Snijders,et al.  Genome‐wide microRNA analysis of HPV‐positive self‐samples yields novel triage markers for early detection of cervical cancer , 2018, International journal of cancer.

[18]  P. Ip,et al.  Oncogenic microRNA signature for early diagnosis of cervical intraepithelial neoplasia and cancer , 2018, Molecular oncology.

[19]  Hiroya Yamada,et al.  Identification of miRNAs in cervical mucus as a novel diagnostic marker for cervical neoplasia , 2018, Scientific Reports.

[20]  M. Pike,et al.  International Endocervical Adenocarcinoma Criteria and Classification (IECC): A New Pathogenetic Classification for Invasive Adenocarcinomas of the Endocervix , 2018, The American journal of surgical pathology.

[21]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[22]  H. Jang,et al.  MiR-9, miR-21, and miR-155 as potential biomarkers for HPV positive and negative cervical cancer , 2017, BMC Cancer.

[23]  Nancy Santesso,et al.  Cytology versus HPV testing for cervical cancer screening in the general population. , 2017, The Cochrane database of systematic reviews.

[24]  A. Etheridge,et al.  A systematic study on dysregulated microRNAs in cervical cancer development , 2016, International journal of cancer.

[25]  I. Kukimoto,et al.  Human papillomavirus genotype distribution in cervical intraepithelial neoplasia grade 2/3 and invasive cervical cancer in Japanese women. , 2014, Japanese journal of clinical oncology.

[26]  J. A. López,et al.  Multistep Model of Cervical Cancer: Participation of miRNAs and Coding Genes , 2014, International journal of molecular sciences.

[27]  Y. Li,et al.  MicroRNA Detection in Cervical Exfoliated Cells as a Triage for Human Papillomavirus–Positive Women , 2014, Journal of the National Cancer Institute.

[28]  G. Sharma,et al.  A Comprehensive Review of Dysregulated miRNAs Involved in Cervical Cancer , 2014, Current genomics.

[29]  Zuhong Lu,et al.  miRNA in Plasma Exosome is Stable under Different Storage Conditions , 2014, Molecules.

[30]  H. Döhner,et al.  Impact of serum storage conditions on microRNA stability , 2012, Leukemia.

[31]  M. Esteller Non-coding RNAs in human disease , 2011, Nature Reviews Genetics.

[32]  Y. Hirai,et al.  Predicting the progression of cervical precursor lesions by human papillomavirus genotyping: A prospective cohort study , 2011, International journal of cancer.

[33]  T. Iftner,et al.  Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. , 2010, Journal of the National Cancer Institute.

[34]  N. Kiviat,et al.  Screening for cervical cancer in the era of the HPV vaccine--the urgent need for both new screening guidelines and new biomarkers. , 2008, Journal of the National Cancer Institute.

[35]  Stijn van Dongen,et al.  miRBase: tools for microRNA genomics , 2007, Nucleic Acids Res..

[36]  Claus Lindbjerg Andersen,et al.  Normalization of Real-Time Quantitative Reverse Transcription-PCR Data: A Model-Based Variance Estimation Approach to Identify Genes Suited for Normalization, Applied to Bladder and Colon Cancer Data Sets , 2004, Cancer Research.

[37]  S. Takigami,et al.  Degradation of serum microRNAs during transient storage of serum samples at 4℃ , 2018, Annals of clinical biochemistry.